Key Highlights

  • Genprex shares closed down 21% at $4.75.
  • The company disclosed a partnership with Roche Diagnostics to validate TROP2 biomarker assay parameters.
  • The initiative aims to refine patient enrollment for REQORSA trials in non-small cell lung cancer.
  • The validation phase is projected for completion by late 2026.

Genprex, Inc. (NASDAQ: GNPX) shares closed down 21% at $4.75 despite the company disclosing a tactical partnership with Roche Diagnostics aimed at validating TROP2 biomarker assay parameters to refine patient enrollment for clinical studies of REQORSA (quaratusugene ozeplasmid) in non-small cell lung cancer (NSCLC).

What Happened

This initiative utilizes Roche's AI-powered, Breakthrough-designated TROP2 antibody assay to substantiate findings that elevated TROP2 (H-scores greater than 100) paired with diminished PTEN expression (H-scores less than 100) serve as predictors for enhanced progression-free survival (PFS).

Roche is slated to execute the validation phase, which is projected for completion by late 2026, allowing Genprex to formalize the biomarker-driven protocol within its ongoing NSCLC clinical development strategy.

Market Reaction

Shares fell 21% despite the partnership announcement, a decline that stands in contrast to the generally constructive framing of a biomarker validation collaboration with an established diagnostics partner.

Outlook

Completion of Roche's validation phase, projected for late 2026, represents the next disclosed milestone for the biomarker-driven protocol within Genprex's NSCLC development strategy.

What partnership did Genprex disclose?

A partnership with Roche Diagnostics to validate TROP2 biomarker assay parameters for REQORSA trials in NSCLC.

Why did Genprex shares fall 21% despite this news?

The disclosed information does not specify a reason for the decline beyond the partnership announcement.

When is the validation phase expected to complete?

Late 2026.